Lineage Therap (LCTX) AI Stock Analysis

• Market Cap: $232.92M
• Dividend Yield: N/A
• Average Volume (3M): 3.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: 19.42%
• EPS Growth: 40.83%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 228,356,300
• 10 Day Avg. Volume: 1,272,631
• 30 Day Avg. Volume: 3,462,568
• PEG Ratio: -1.09
• Price to Book (P/B): 3.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.49
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 5.38
• Enterprise Value/Gross Profit: 19.68
• Enterprise Value/Ebitda: -2.14
• 1Y Price Target: $4.13
• Price Target Upside: 330.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 62 Neutral
• Price Target: $1.00 ▲(4.17%Upside)

Lineage Therap's overall score reflects the company's strong technical indicators and positive corporate developments, countered by financial performance challenges and speculative valuation. Key program advancements and financial stability provide growth potential, though risks remain in execution and external dependencies.

Positive Factors

Clinical Progress

With Roche’s backing, Lineage remains well ahead in clinical progress, building momentum in the field.

Therapeutic Efficacy

The benefits observed in the Phase 1/2a study remain after three years post-dosing, supporting the potential of OpRegen as a one-time therapy that can alter the course of this progressive disease.

Negative Factors

Market Competition

Unprecedented data continue to excite in a big way vs. approved GA products, providing major and significant differentiation vs. currently approved GA drugs.

Regulatory Challenges

Genentech moving into a randomized controlled trial could trigger warrants worth an additional $36M in gross proceeds, but may also involve complexities of further regulatory requirements.

Lineage Therap Business Overview & Revenue Model

Company Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

How the Company Makes Money

Lineage Cell Therapeutics makes money primarily through the development and commercialization of its cell-based therapies. The company generates revenue through strategic partnerships, licensing agreements, and collaboration with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and potential royalties on sales of developed products. Additionally, Lineage may engage in government or private grants and contracts to support its research and development efforts. The company's ability to advance its product candidates through clinical trials and receive regulatory approval is a significant factor in its potential earnings, as successful commercialization can lead to substantial revenue streams from product sales.

Lineage Therap Financial Statement Overview

Summary

Lineage Therap's financials reflect typical early-stage biotech challenges. Despite strong gross margins and low leverage, negative net profit margins and reliance on external funding due to negative cash flow highlight risks. Efforts to improve operating efficiency and revenue growth are needed to enhance financial stability.

Income Statement

Lineage Therap's income statement reveals challenges in achieving profitability with negative EBIT and EBITDA margins despite a slight increase in revenue. The gross profit margin remains relatively strong at around 97% for the TTM. However, the net profit margin is negative, and revenue growth has been inconsistent, highlighting the company's struggle to convert sales into profits.

Balance Sheet

The balance sheet shows a moderate financial position with a debt-to-equity ratio of about 0.03, indicating low leverage. The equity ratio stands at 69.5%, reflecting significant equity financing. However, the return on equity is negative due to ongoing net losses, suggesting inefficiencies in generating returns from shareholder capital.

Cash Flow

The cash flow statement indicates negative free cash flow, with a slight improvement in operating cash flow compared to net income. The free cash flow to net income ratio is negative, showing challenges in converting earnings into cash flow. Financing activities have been a key source of cash, suggesting reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.50M	8.95M	14.70M	3.90M	773.00K
Gross Profit	9.16M	8.27M	13.97M	2.47M	388.00K
EBITDA	-20.87M	-24.04M	-21.79M	-48.34M	-24.41M
Net Income	-18.61M	-21.49M	-26.35M	-38.56M	-20.68M
Balance Sheet
Total Assets	113.22M	101.02M	123.66M	174.54M	107.95M
Cash, Cash Equivalents and Short-Term Investments	47.80M	35.49M	57.88M	58.36M	41.56M
Total Debt	2.51M	2.95M	3.90M	2.80M	3.30M
Total Liabilities	36.21M	39.00M	51.73M	83.65M	12.82M
Stockholders Equity	78.38M	63.42M	73.34M	92.22M	96.20M
Cash Flow
Free Cash Flow	-23.66M	-29.24M	646.00K	-23.91M	-19.82M
Operating Cash Flow	-23.09M	-28.57M	1.06M	-23.56M	-19.75M
Investing Cash Flow	-2.31M	46.45M	-46.16M	9.74M	13.04M
Financing Cash Flow	35.86M	6.42M	1.63M	36.93M	29.86M

Lineage Therap Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LCTX, the sentiment is Positive. The current price of 0.96 is below the 20-day moving average (MA) of 0.99, above the 50-day MA of 0.76, and above the 200-day MA of 0.66, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 56.41 is Neutral, neither overbought nor oversold. The STOCH value of 40.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LCTX.

Lineage Therap Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EDIT	66 Neutral	$237.74M	―	-140.82%	―	-48.37%	-44.70%
LCTX	62 Neutral	$232.92M	―	-21.40%	―	19.42%	40.83%
CLLS	58 Neutral	$131.39M	―	-58.55%	―	825.97%	38.32%
Sector *	52 Neutral	$7.34B	-0.07	-63.86%	2.34%	16.17%	0.23%
NKTX	39 Underperform	$129.85M	―	-26.10%	―	―	30.76%
CTNM	39 Underperform	$99.09M	―	-91.32%	―	-100.00%	-244.85%
NMRA	33 Underperform	$226.45M	―	-79.05%	―	―	-0.42%

Lineage Therap Corporate Events

Lineage Therap Holds Annual Meeting, Elects Directors

On June 26, 2025, Lineage Therap held its Annual Meeting, where shareholders elected seven directors to the board, ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved executive compensation on an advisory basis, and approved an EIP Amendment. These decisions reflect shareholder support for the company’s current leadership and strategic direction, potentially impacting its governance and financial practices.

The most recent analyst rating on (LCTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.

Lineage Therap Reports Promising OpRegen Study Results

Lineage Cell Therapeutics announced the 36-month visual acuity results from a Phase 1/2a clinical study of RG6501 (OpRegen) in patients with geographic atrophy secondary to age-related macular degeneration. The results, presented at Clinical Trials at the Summit 2025, showed sustained improvement in visual acuity and retinal structure in patients who received extensive OpRegen cell therapy coverage, suggesting potential long-term benefits of the therapy. These findings could enhance Lineage’s position in the biotechnology industry by demonstrating the efficacy of their cell therapy in treating advanced ophthalmic conditions.

The most recent analyst rating on (LCTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.